"Treat diseases locally" is a mantra espoused by a growing number of companies but few as yet have actually mustered the means to do so. TARIS Biomedical believes it has what it takes to become a pioneer of minimally invasive drug delivery devices. Its first product offering will be a pretzel-shaped device the size of a paper clip that will release medication inside the bladder, initially as a treatment for interstitial cystitis.
99 Hayden Avenue
Suite 100
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.
